ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,035Medicare Part D Prescriptions Filled, Including Refills
$467K Total Retail Price of All Prescriptions
526 Patients Receiving at Least One Drug in Part D
98%Patients 65 Years and Older
12% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
OMEPRAZOLE 549 536
LEVOTHYROXINE SODIUM 406 403
LISINOPRIL 308 301
AMLODIPINE BESYLATE 302 302
HYDROCODONE-ACETAMINOPHEN 283 278 S3
SIMVASTATIN 265 263
LOSARTAN POTASSIUM 253 253
CITALOPRAM HBR 209 205
METOPROLOL SUCCINATE 191 189
METFORMIN HCL 188 176
ALENDRONATE SODIUM 174 173
ZOLPIDEM TARTRATE 158 158
POTASSIUM CHLORIDE 156 156
GABAPENTIN 110 110
PAROXETINE HCL 103 101
TRAMADOL HCL 101 101
NAMENDA 95 95
WARFARIN SODIUM 91 91
FUROSEMIDE 90 90
PRAVASTATIN SODIUM 88 88
CARVEDILOL 88 88
SYNTHROID 85 85
TRIAMTERENE-HCTZ 83 83
FLUTICASONE PROPIONATE 82 82
DONEPEZIL HCL 81 81
HYDROCHLOROTHIAZIDE 77 76
TRAZODONE HCL 76 76
ATORVASTATIN CALCIUM 75 75
METOPROLOL TARTRATE 75 75
LOSARTAN-HYDROCHLOROTHIAZIDE 70 70
CIPROFLOXACIN HCL 68 68
PANTOPRAZOLE SODIUM 62 62
LISINOPRIL-HYDROCHLOROTHIAZIDE 62 62
ROPINIROLE HCL 60 60
PRAMIPEXOLE DIHYDROCHLORIDE 60 60
BENICAR 54 54
FLUOXETINE HCL 53 50
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 20, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.